A 62-year-old woman with Stage III endometrial cancer (Grade 3 serous adenocarcinoma with pelvic lymph node metastases) has completed total abdominal hysterectomy and bilateral salpingo-oophorectomy. What is the drug of choice for adjuvant chemotherapy?

Explanation

## Adjuvant Chemotherapy for Advanced Endometrial Cancer ### Disease Profile **Key Point:** Stage III, Grade 3 serous adenocarcinoma is a high-risk, aggressive tumour with poor prognosis. Serous histology is inherently chemotherapy-responsive and does NOT respond well to progestin therapy. ### Standard Chemotherapy Regimen **High-Yield:** **Paclitaxel + carboplatin** is the gold-standard first-line adjuvant chemotherapy for advanced-stage (III–IV) endometrial cancer, particularly non-endometrioid histologies (serous, clear cell). **Clinical Pearl:** This regimen is based on: - High response rates in serous endometrial cancers - Proven survival benefit in Stage III–IV disease - Standard dosing: paclitaxel 175 mg/m² IV over 3 hours, carboplatin AUC 5–6 IV, every 3 weeks for 6 cycles ### Why Not Progestin Therapy? **Warning:** Progestins are ineffective in serous adenocarcinoma because: - Serous tumours lack progesterone receptors - They are hormone-independent and aggressive - Progestins are reserved for low-grade, endometrioid, hormone-responsive cancers ### Why Not Hormonal Therapy? **Key Point:** Tamoxifen and aromatase inhibitors (letrozole) are NOT used for endometrial cancer: - ~~Tamoxifen~~ increases endometrial cancer risk; it is contraindicated - ~~Letrozole~~ is used for breast cancer, not endometrial malignancy ### Treatment Algorithm for Endometrial Cancer ```mermaid flowchart TD A[Endometrial Cancer]:::outcome --> B{Stage and Grade?}:::decision B -->|Stage IA-IB, Grade 1-2| C[Progestin therapy]:::action B -->|Stage III-IV or Grade 3| D{Histology?}:::decision D -->|Endometrioid| E[Chemotherapy ± Progestin]:::action D -->|Serous/Clear Cell| F[Paclitaxel + Carboplatin]:::action C --> G[12-24 months treatment]:::action F --> H[6 cycles, 3-weekly]:::action ``` | Scenario | First-Line Drug | | --- | --- | | Stage IA–IB, Grade 1–2, endometrioid | Progestin (megestrol or MPA) | | Stage III–IV, serous/clear cell | Paclitaxel + carboplatin | | Stage III–IV, Grade 3 endometrioid | Paclitaxel + carboplatin ± progestin | | Recurrent/metastatic | Paclitaxel + carboplatin; consider pembrolizumab if MSI-H | **Citation:** [cite:Robbins 10e Ch Endometrial Neoplasia], [cite:Harrison 21e Ch 85]